Evidence map›Paper›PMID 36353219›Full record

ReviewFrontiers in medicine2022

Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems.

Ryu Watanabe, Tadashi Okano, Takaho Gon, Naofumi Yoshida, Kazuo Fukumoto, Shinsuke Yamada, Motomu Hashimoto

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution.

Ryu WatanabeDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Tadashi OkanoDepartment of Orthopaedic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Takaho GonDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Naofumi YoshidaDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Kazuo FukumotoDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Shinsuke YamadaDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Motomu HashimotoDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Osaka Metropolitan University

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past several decades, the treatment of rheumatoid arthritis (RA) has advanced significantly, and clinical, structural, and functional remission are achievable therapeutic goals. However, a substantial number of patients show resistance to multiple drugs. In particular, patients whose disease activity cannot be controlled despite the use of two or more biological disease-modifying antirheumatic drugs (DMARDs) or targeted synthetic DMARDs (tsDMARDs) with different mechanisms of action (MOA) have recently been referred to as having difficult-to-treat RA (D2T RA). D2T RA is a heterogeneous and multifactorial disease state, and the major problems are uncontrolled disease activity and decreased quality of life, as well as the economic burden due to frequent healthcare utilization and multiple admissions. Since the concept of D2T RA is relatively new and publication regarding D2T RA is limited, the mechanism underlying DMARD inefficacy and which factors form a "difficult-to-treat" state in such patients are not yet fully understood. It is also possible that factors contributing to D2T RA may differ by patient, sex, country, and race. The present Mini Review introduces the current concept and unsolved problems of D2T RA, including the definition, prevalence, and factors contributing to D2T RA. We then discuss the management and therapeutic strategies for D2T RA. Finally, we explore a clinical approach to prevent patients from developing D2T RA.

Indexed as

difficult-to-treatdisease-modifying antirheumatic drugsdrug resistancemethotrexatepulmonary involvement

Identifiers

PMID36353219
PMCPMC9637686
OpenAlexW4307267973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.